July 20, 2017 / 11:45 AM / a month ago

BRIEF-Exelixis announces settlement of dispute with Genentech

July 20 (Reuters) - Exelixis Inc

* Exelixis announces settlement of dispute with Genentech regarding companies’ collaboration agreement for Cobimetinib

* Exelixis Inc - ‍Companies define new revenue and cost-sharing terms for all commercial applications of Cobimetinib​

* Exelixis Inc - ‍Cobimetinib's clinical development program includes three ongoing or planned phase 3 pivotal trials​

* Exelixis Inc - ‍Settlement of dispute with Genentech, member of Roche Group, on collaboration for development,commercialization of Cobimetinib

* Exelixis Inc - ‍Exelixis remains eligible for royalties on Cotellic sales according to terms of original 2006 agreement​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below